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Endogenous adenosine A2B receptors (A2BAR) mediate cAMP accumulation in HEK 293 cells. Here we have
used a biosensor to investigate the mechanism of action of the A2BAR antagonist PSB 603 in HEK 293 cells.
The A2A agonist CGS 21680 elicited a small response in these cells (circa 20% of that obtained with NECA),
suggesting that they also contain a small population of A2A receptors. The responses to NECA and
adenosine were antagonised by PSB 603, but not by the selective A2AAR antagonist SCH 58261. In
contrast, CGS 21680 responses were not antagonised by high concentrations of PSB 603, but were
sensitive to inhibition by SCH 58261. Analysis of the effect of increasing concentrations of PSB 603 on
the response to NECA indicated a non-competitive mode of action yielding a marked reduction in
the NECA EMAX with no significant effect on EC50 values. Kinetics analysis of the effect of PSB 603 on
the A2BAR-mediated NECA responses confirmed a saturable effect that was consistent with an allosteric
mode of antagonism. The possibility that PSB 603 acts as a negative allosteric modulator of A2BAR
suggests new approaches to the development of therapeutic agents to treat conditions where adenosine
levels are high.
 2017 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Adenosine acts via four (A1, A2A, A2B and A3) specific G protein-
coupled receptors (GPCRs) [1]. The A1 and A3 receptors couple to
Gi/o proteins and inhibit adenylyl cyclase activity whilst the A2A
and A2B receptors preferentially couple to Gs proteins and stimulate
the formation of cyclic AMP (cAMP) [1–3]. The crystal structure of
theA2A receptor (A2AAR) inbothantagonist [4] andagonist [5]bound
conformations has been determined in recent years. The adenosine
A2B receptor (A2BAR), which is closely related to the A2AAR, is the
least well defined of the four adenosine receptors and has low affin-
ity for the endogenous agonist, adenosine [3,6]. A2BARs have been
reported to have important roles in inflammation, fibrosis, angio-
genesis and tumourprogression [3,7–11]making theman important
therapeutic target for drug discovery.
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the A1, A3 and A2A receptors, these are more limited for A2BAR
[3,12–15]. However, a selective A2BAR antagonist has been
recently developed (PSB 603) which has also been used as a radi-
oligand (3H-PSB-603) [16]. This compound has been used to
investigate the amino acids involved in the interaction of ago-
nists and antagonists with A2BAR [6]. This study showed that
whilst Trp247, Val250 (both in transmembrane 6;TM6), and
Ser279 (TM7) were important for the binding of nucleoside-
based agonists, Leu81 (TM3), Asn186 (TM5) and Val250 (TM6)
were crucial for binding of the xanthine-derived antagonist PSB
603 [6]. These data suggest that PSB 603 may bind to a different
set of amino acids to those used by the endogenous ligand ade-
nosine, and this raises the possibility of an allosteric mechanism
of action.
Allosteric ligands bind to a topographically distinct site (allos-
teric) from that occupied by the endogenous agonist (orthosteric
site) and elicit a conformational change that can lead to alter-
ations in the affinity or efficacy of the ligand occupying the
orthosteric binding site [17–20]. Key features of an allosteric
mechanism of action are that the effect is saturable (i.e. reaches
a limiting maximal effect), can depend on the specific ligand
occupying the orthosteric site (probe dependence) and provides
scope for both positive and negative effects on ligand binding
and/or function [17–20]. An allosteric mechanism of action can
provide a drug with a number of potential advantages such as
introducing greater selectivity for the target, producing an effect
that may depend on concurrent binding of the natural ligand
and, in the case of negative allosteric regulators, a non-
competitive effect that is resistant to high concentrations of
the endogenous orthosteric agonist. This may have advantage
for A2BAR directed therapeutics that are designed to address con-
ditions such as ischemia and inflammation where levels of ade-
nosine may be very high.
In the present study we have characterised the cAMP responses
elicited by endogenous A2BAR expressed in HEK 293 cells [21] with
particular reference to the potential for allosteric interactions. We
also provide evidence for a minor population of endogenous A2AAR
in this cell line. To help with this characterisation, we have used
the following adenosine receptor antagonists (their respective Ki
values for A2AAR and A2BAR given in parentheses): XAC (1 nM
[22], 73 nM [23]); ZM 241385 (1.4 nM, 32 nM [23]); SCH 58261
(0.6 nM, 5011 nM [24]) and PSB 603 (Ki > 10,000 nM, 0.5 nM
[16]). We have studied real-time kinetic changes in cAMP levels
using the GloSensorTM biosensor (Promega) in intact living cells
[25,26]. The GloSensorTM technology is based on an engineered form
of firefly luciferase encompassing a cAMP-binding domain from
protein kinase A (RIIbB; [26]). Upon binding of cAMP, in the pres-
ence of the GloSensorTM substrate [26], the resultant conforma-
tional change in the GloSensorTM biosensor leads to light emission
that can be detected by an automated plate-reader. This assay
lends itself nicely to the study of GPCR mediated cAMP modulation
in both endogenous and over expressed systems. For example, it
has been used to study the Gas-coupled b2-adrenergic receptor
found endogenously in HEK293 cells [27] or over-expressed in
HEK293 cells, and used to dissect intracellular signalling [28].
Furthermore, Gai/o-coupled responses can be determined from
their ability to inhibit forskolin-stimulated cAMP responses (e.g.
for the metabotropic glutamate receptor expressed in CHO K1 cells
[29]) or reduce basal levels of cAMP (e.g. the succinate receptor 1 in
HEK293 cells [30]). Here we have used the GloSensorTM biosensor
to study the pharmacological profile, and mechanism of action of
PSB 603 as an antagonist, of Gs-coupled A2BARs endogenously
expressed in HEK293 cells.2. Materials and methods
2.1. Cultured cells
The cAMP GloSensorTM (20F) biosensor [26] expressed in HEK293
(HEK293G) cells was obtained from Promega (Madison, WI).
HEK293G cells were maintained in Dulbecco modified eagles med-
ium (DMEM) supplemented with 2 mM L-glutamine, 10% FCS (fetal
calf serum) and 200 lg/ml hygromycin B at 37 C 5% CO2. Once con-
fluent, cells were dislodged from the flask surface by gentle shaking
after incubation in 0.25% trypsin and cell pellet formed following 5
min 1000 g centrifugation. For the GloSensorTM assay, cells were re-
suspended in DMEM supplemented with 2 mM L-glutamine and
10% FCS and seeded at a density of 35000 cells/well on poly-l-
lysine treated clear bottomedwhitewalled96well plates. Cellswere
incubated at 37C 5% CO2 overnight prior to assay.
2.2. GloSensorTM assay
The GloSensorTM assay was carried out as per manufacturer’s
instructions (Promega, Madison, WI, USA). Briefly, this was as fol-
lows; Media was aspirated and cells were incubated in 100 ml HBSS
(HEPES buffered saline solution pH 7.45; Sodium pyruvate 2 mM,
NaCl 145 mM, D-Glucose 10 mM, KCL 5 mM, MgSO47H2O 1 mM,
HEPES 10 mM, CaCl2 1.7 mM, NaHCO3 1.5 mM) containing 4–6%
GloSensorTM cAMP reagent and incubated for 2 h at final experi-
mental temperature of 35C. Luminescence was measured on an
EnVision Multilabel Plate Reader (Perkin Elmer, Massachusetts,
USA) continuously over 60 min, averaging 1 read per well every
1.5 min, following the addition of 100 ml HBSS in the presence or
absence of Forskolin (10 nM–10 mM), NECA (50-(N-Ethylcarboxamido)
adenosine, 10 nM-30 mM), Adenosine (100 nM-100 mM), BAY 60-6583
(2-[[6-Amino-3,5-dicyano-4-[4-(cyclopropylmethoxy)phenyl]-2-
pyridinyl]thio]-acetamide, 1 pM-30 lM) or CGS 21680 (4-[2-[[6-
Amino-9-(N-ethyl-b-D-ribofuranuronamidosyl)-9H-purin-2-yl]amino]
ethyl]benzene propanoic acid hydrochloride, 30 nM-30 mM). Antago-
nist action was monitored following 30 min pre-incubation with
HBSS in the presence or absence of XAC (xanthine amine congener),
PSB 603 (8-[4-[4-(4-Chlorophenzyl)piperazide-1-sulfonyl)phenyl]]-
1-propylxanthine), ZM 241385 (4-(2-[7-Amino-2-(2-furyl)[1,2,4]
triazolo[2,3-a][1,3,5]triazin-5-ylamino]ethyl)phenol or SCH 58261
(2-(2-Furanyl)-7-(2-phenylethyl)-7H-pyrazolo [4,3-e][1,2,4] triazolo
[1,5-c]pyrimidin-5-amine).
2.3. Data analysis
Determinations of agonist potency, antagonist affinity and equi-
librium dissociation constants were made by fitting data within
GraphPad Prism version 5.03 for Windows (GraphPad Software,
San Diego California USA, www.graphpad.com).
To obtain the antagonist equilibrium dissociation constants (KB)
a modified form of the Gaddum equation was used as described by
Lazareno and Birdsall [31]:
KB ¼ IC50½A=ECF  1
where IC50 is the molar concentration of antagonist (B) required to
decrease by 50% the response mediated by the fixed molar concen-
tration of agonist (A) in the absence of antagonist; and ECF the
molar concentration of agonist that, in the absence of antagonist,
mediated the same response as that obtained in the presence of
an IC50 concentration of antagonist. Agonist concentration response
curves were simultaneously obtained (in the absence of antagonist).
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the agonist concentration response curves in the presence of a fixed
concentration of antagonist using the following equation:
DR ¼ 1þ ½B
KBTable 1
pIC50 and apparent dissociation equilibrium constants for adenosine A2 receptor antagoni
Agonist XAC
NECA pIC50
IC50 (nM)
6.93 ± 0.10 (6)
134.8 ± 34.3
-Log KB
KB (nM)
7.90 ± 0.10 (6)
14.4 ± 3.7
CGS 21680 pIC50
IC50 (nM)
7.02 ± 0.09 (5)
103.9 ± 18.7
-Log KB
KB (nM)
7.89 ± 0.09 (5)
14.0 ± 2.5
Adenosine pIC50
IC50 (nM)
7.15 ± 0.12 (4)
97.0 ± 47.0
-Log KB
KB (nM)
7.48 ± 0.12 (4)
45.6 ± 22.1
BAY 60-6583 pIC50
IC50 (nM)
6.81 ± 0.10 (6)
173.8 ± 33.9
-Log KB
KB (nM)
7.50 ± 0.10 (6)
35.6 ± 6.9
IC50 values and apparent dissociation equilibrium constants (KB) were calculated from N
concentration curves in the absence of antagonist. Data are expressed as mean ± S.E.M
dissociation constant for ZM 241385 following CGS 21680 stimulation is significantly diff
.0001; 1-way ANOVA). nd – Not determined because of lack of antagonism (see Fig. 6).
Table 2
Agonist pEC50 and Emax values obtained in the presence of increasing concentrations of PS
NECA Adenosine
PSB 603 (nM) pEC50 Emax pEC50
0 5.77 ± 0.08 112.43 ± 3.08 4.97 ± 0.0
30 5.66 ± 0.20 93.60 ± 8.38 4.56 ± 0.0
100 5.86 ± 0.13 53.59 ± 8.68** 4.34 ± 0.0
300 5.68 ± 0.25 43.22 ± 7.60** 4.03 ± 0.1
pEC50 and Emax values obtained for NECA and adenosine obtained in the presence of incr
response obtained with 10 lM NECA, 100 lM adenosine or 10 mM BAY 60-6583. Signi
indicated (**p < .01, ****p < .0001, 1-way ANOVA). Data are expressed as mean ± S.E.M. of
((a)
Fig. 1. Forskolin – and NECA – stimulated cAMP Glosensor luminescence. (a) Glosensor
NECA (10 mM). Data are mean ± S.E.M. of triplicate determinations obtained in a single rep
data were obtained in 8 (Forskolin) and 21 (NECA) separate experiments. (b) Representa
in a single experiment. Bars show the peak luminescence response to 10 lM forskolin (
experiments.where DR (dose ratio) is the ratio of the agonist concentration
required to stimulate an identical response in the presence and
absence of antagonist, [B].
Statistical significance was determined, where appropriate,
using Student’s t-test, linear regression or one-way ANOVA with
either Bonferroni’s (Table 1) or Dunnett’s (Table 2) multiple
comparison test if p < .05 (statistically significant). A minimum ofsts.
PSB 603 ZM 241385 SCH 58261
7.53 ± 0.22 (6)
49.8 ± 19.1
7.11 ± 0.10 (5)
84.4 ± 15.8
nd
8.50 ± 0.22 (6)
5.3 ± 2.0
8.08 ± 0.10 (5)
9.0 ± 1.7
nd
nd 8.85 ± 0.18 (7)
2.3 ± 0.9
7.64 ± 0.11 (8)
28.4 ± 5.8
nd 9.72 ± 0.181 (7)
0.3 ± 0.1
8.51 ± 0.11 (8)
3.8 ± 0.8
7.56 ± 0.43 (5)
140.9 ± 118.4
7.66 ± 0.14 (5)
28.1 ± 10.6
nd
7.89 ± 0.43 (5)
66.3 ± 55.7
7.99 ± 0.14 (5)
13.2 ± 5.0
nd
7.86 ± 0.13 (6)
17.4 ± 5.4
7.05 ± 0.16 (6)
119.8 ± 38.5
nd
8.55 ± 0.13 (6)
3.6 ± 1.1
7.74 ± 0.16 (6)
24.5 ± 7.9
nd
ECA, CGS 21680, adenosine and BAY 60-6583 competition curves alongside agonist
. of n separate experiments (shown in parentheses). 1The apparent equilibrium
erent to that observed following NECA, BAY 60-6583 and adenosine stimulation (p <
B 603.
BAY 60-6583
Emax pEC50 Emax
4 107.33 ± 3.67 6.39 ± 0.04 104.40 ± 5.14
8** 99.97 ± 10.83 5.80 ± 0.18 82.23 ± 1.64
8** 67.72 ± 5.94** 5.34 ± 0.22** 68.66 ± 6.78
3** 57.36 ± 6.13** 4.44 ± 0.13**** 99.35 ± 26.61
easing concentrations of PSB 603. EMAX values are expressed as a percentage of the
ficant differences to that seen in the absence of antagonist with each agonist are
4 (NECA), 7 (adenosine) or 3 (BAY 60-6583) separate experiments.
b)
luminescence time courses following stimulation by increasing forskolin (10 mM) or
resentative experiment and expressed as relative luminescence units (RLU). Similar
tive concentration response curve for NECA obtained from triplicate determinations
F) and that seen with vehicle alone (V). Similar data were obtained in 21 separate
(b)(a)
(c) (d)
Fig. 2. Kinetic profile of increasing concentrations of (a) forskolin, (b) NECA, (c) BAY 60-6583 or (d) CGS 21680 – stimulated cAMP Glosensor luminescence. Data are mean ± S.
E.M. expressed as a percentage of the peak luminescence obtained in 8 (a), 21 (b), 3 (c) or 4 (d) separate experiments each performed in triplicate. (For interpretation to
colours in this figure, the reader is referred to the web version of this paper.)
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tal work. This was based on the variance of the data obtained and
power analysis that predicted a high probability of observing small
differences in measured parameters. For example, the probability
of detecting a change in pEC50 of 0.5 (3-fold) with n = 3 is 0.89.
For n = 4 this increased to 0.96.
2.4. Drugs, chemical reagents and other materials
GlosensorTM cAMP Human Embryonic Kidney 293 cell line
(Hek293G) and GloSensorTM cAMP Reagent were obtained from Pro-
mega (Wisconsin, USA). Forskolin, NECA, Adenosine, XAC and SCH
58261 were from Sigma-Aldrich (Missouri, USA). PSB 603, ZM
241385, BAY 60-6583 and CGS 21680 hydrochloride were from
Tocris Bioscience (Bristol, UK). Adenosine Deaminase (ADA) was
from Roche (Mannheim, Germany). Hygromycin B was from Invit-
rogen (Paisley, UK). L-glutamine, trypsin and FCS were from Lonza
(Verviers, Belgium). All other chemicals were from Sigma-Aldrich
(Missouri, USA).
3. Results
3.1. Kinetic profile of forskolin- and NECA- stimulated GloSensorTM
luminescence in HEK293G cells
The effect of direct activation of adenylyl cyclase by forskolin on
cAMP production and subsequent GloSensorTM luminescence inHEK293G cells is shown in Figs. 1a and 2a. Forskolin (10 mM) stim-
ulated a concentration-dependent increase in luminescence which
was followed (after achievement of the peak response) by a slow
decline in the luminescence signal (Figs. 1a and 2a). We have pre-
viously reported that the HEK-293 cells express an endogenous
adenosine A2BAR [21]. Stimulation of this receptor via the non-
selective adenosine receptor agonist NECA also elicited a
concentration-dependent increase in luminescence (Fig. 1b).
Whilst the magnitude of raw luminescence observed was dependent
on biosensor expression level and GloSensorTM substrate concentra-
tion in a given experimental plate, the luminescent output afforded
by 10 lM NECA was consistently greater (P < 0.05, unpaired t-test)
than that of 10 lM forskolin and both were considerably greater
than that observed with vehicle (HBSS) alone (Fig. 1a).
It was evident that the rate of luminescent decay at the two
highest NECA concentrations tested (10–30 mM) was markedly
greater than that observed with a lower concentration of NECA
(3 lM) giving an equivalent sized response (Fig. 2b). This was
not seen with forskolin (Fig. 2a). The most likely explanation for
this phenomenon is that receptor desensitization is occurring at
the highest concentrations of NECA employed in this study. To
investigate the rate of decline of the GloSensorTM response upon ter-
mination of A2BAR stimulation, as would occur when the agonist is
removed or the receptor desensitized, we investigated the effect of
addition of adenosine deaminase (ADA), an enzyme that metabo-
lises adenosine to inosine, on an established adenosine response
Fig. 3. The influence of adenosine deaminase on the kinetic profile of adenosine
mediated cAMP production. Glosensor luminescence time course following
stimulation by 1 mM adenosine and subsequent addition of HBSS (open symbols)
or 2 U.ml1 adenosine deaminase (ADA; closed symbols) at the peak luminescence
obtained (arrow). Data represent mean ± S.E.M. of 6 separate experiments each
performed in triplicate, RLU; raw luminescence units.
Fig. 4. Concentration response curves for agonist-stimulated cAMP Glosensor
luminescence responses in HEK 293 cells giving pEC50s of 6.05 ± 0.08 (n = 21,
NECA), 4.69 ± 0.08 (n = 13, adenosine), 6.19 ± 0.02 (n = 3, BAY 60-6583) and 6.45 ±
0.06 (n = 13, CGS 21680). Data represent mean ± S.E.M of the peak luminescence
response in individual experiments carried out in triplicate. Data are expressed as a
percentage of the peak luminescence response obtained with 10 mM NECA
measured in the same experiment.
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nosine rapidly reduced the luminescence output to basal levels
within a few minutes (Fig. 3). In contrast, addition of HBSS in place
of ADA resulted in a slow decline (Fig. 3) similar to that seen with
forskolin or 3 lM NECA alone (Fig. 2a-b).3.2. Characterisation of A2BAR and A2AAR responses in the HEK293G
cell line
Concentration-response curves for agonist-stimulated GloSen-
sorTM responses are shown in Fig. 4, with the selective A2B agonistBAY 60-6583 behaving a partial agonist relative to that of the
endogenous agonist adenosine and its analogue NECA. Most
notably the A2AAR-selective agonist CGS 21680 was able to stimu-
late a small but significant response within the HEK293G cell line
(18.6 ± 4.5% that obtained with NECA; n = 12; P < 0.01; paired t test
relative to basal), suggesting that the HEK293G cell line contained
a mixed population of A2AAR and A2BAR. Interestingly, BAY 60-
6583 gave a similar time course (providing evidence of desensitiza-
tion at higher agonist concentrations) to that observed with NECA
(Fig. 2c) whilst CGS 21680 did not (Fig. 2d). In addition the
concentration-response curve for NECA had a Hill slope signifi-
cantly less than unity (0.75; p < .001; Partial F test) which would
be consistent with the presence of more than one component, sim-
ilar to that seen previously in HMC-1 cells, which also expresses
both A2AAR and A2BAR subtypes [32].
The partial agonist nature of the response to the A2B-selective
agonist BAY 60-6583 at the A2BAR was confirmed in combination
experiments with NECA (Fig. 5a). Thus, increasing concentrations
of BAY 60-6583 were able to antagonise the response to a fixed
concentration of NECA (10 mM) whilst a fixed concentration of
BAY 60-6583 (10 mM) was able to shift the concentration-
response curve to NECA to higher agonist concentrations
(Fig. 5a). In marked contrast, the responses to the A2B-selective
agonist BAY 60-6583 and the A2A selective agonist CGS 21680 were
simply additive at low concentrations of each agonist, but reached
a maximum that appeared to be entirely determined by the max-
imum response to BAY 60-6583 (Fig. 5b). These data suggest that
the overall response to a combination of A2A and A2B receptor stim-
ulation is largely determined by the maximum A2B signal in this
cell line.
To investigate this further we examined the effect of subtype-
selective antagonists on the responses to 10 mM NECA, 10 lM ade-
nosine, 1 lM BAY 60-6583 or 1 lM CGS 21680 (Fig. 6). Pre-
incubation with the non-selective adenosine receptor antagonist
XAC inhibited the response to 10 mM NECA in a concentration-
dependent manner, completely abolishing the response at 10 mM
XAC (Fig. 6a). Similarly, the highly selective A2BAR antagonist PSB
603 produced a concentration-dependent inhibition of the NECA
response, however the maximal inhibition achieved was only
81.7 ± 2.4% (n = 7, 1-way ANOVA P < .001 when compared to the
response following stimulation with vehicle alone) of the maximal
response to NECA (Fig. 6a). It is unlikely that this residual response
following pre-incubation with the highest PSB 603 concentration is
due to an A2AAR population since the A2AAR antagonist ZM 241385
also produced a concentration dependent inhibition of the
response to NECA with complete inhibition at 10 mM (Fig. 6a).
However the equilibrium dissociation constant obtained following
ZM 241385 pre-incubation was entirely consistent with an A2BAR-
mediated response (Table 1; [24,33]). Consistent with this sugges-
tion, the more selective A2AAR antagonist SCH 58261 [34] failed to
inhibit the response to NECA at all concentrations studied (Fig. 6a).
Inclusion of 100 nM SCH 58261 in the competition curve obtained
with PSB 603 did not produce a greater maximal inhibition of the
response to NECA (Fig. 7).
Antagonism of the response to adenosine and BAY 60-6583 pro-
duced profiles that resembled that of NECA (Fig. 6b-c). Similar to
the data obtained with NECA, 10 mM PSB 603 produced only 80.5
± 3.0% inhibition of the response to 10 mM adenosine (Fig. 6b, 1-
way ANOVA P < .001 when compared to the response following
stimulation with vehicle alone). SCH 58261 appeared to enhance
the production of cAMP at lower concentrations whilst inhibiting
approximately 35% of the adenosine response at the highest con-
centration tested, although neither effect was statistically signifi-
cant. SCH 58261 was a weak antagonist of the response to BAY
60-6583. The response to this agonist was potently antagonised
by PSB 603 and was able to completely abolish the response to
)b()a(
Fig. 5. Concentration response curves following (a) BAY 60-6583 or NECA addition and (b) BAY 60-6583 or CGS 21680 addition in the presence (open symbol) or absence
(closed symbol) of 10 mM of the alternate agonist. Data represent mean ± S.E.M of the peak luminescence response in individual experiments carried out in triplicate. Data are
expressed as a percentage of the peak luminescence response to 10 lMNECA obtained in three separate experiments. In each individual experiment triplicate determinations
were made.
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for responses to the selective A2AAR agonist, CGS 21680 (Fig. 6d).
XAC, ZM 241385 and SCH 58261 conferred complete
concentration-dependent antagonism of the CGS 21680 response.
The highly selective A2BAR antagonist, PSB 603, was unable to inhi-
bit the CGS 21680 response at any of the concentrations tested.
Apparent equilibrium dissociation constants for the different
antagonists from this analysis are shown in Table 1.
3.3. Mechanism of A2BAR antagonism by PSB 603
In order to further characterise the mechanism of action of
these antagonists at the adenosine A2 receptor population within
HEK293G cells, concentration-response curves were obtained for
NECA, adenosine, BAY 60-6583 and CGS 21680 following pre-
incubation with increasing concentrations of different antagonists.
Pre-incubation with increasing concentrations of both XAC and ZM
241385 elicited parallel rightwards shifts of the concentration-
response curves to NECA (Fig. 8a, b) consistent with a competitive
interaction between agonist and antagonist at the A2BAR. Analysis
of these shifts yielding pA2 (log KB) values of 7.50 ± 0.09 (n = 4)
and 8.02 ± 0.10 (n = 3) for XAC and ZM 241385 respectively. These
are similar to the values obtained in Table 1. In contrast, the A2AAR
-selective antagonist SCH 58261 did not shift the NECA concentra-
tion response curve to higher agonist concentrations, and only
shifted the adenosine response curve at the highest concentration
(100 nM) tested (Fig. 8c-d). However, both SCH 58261 and ZM
241385 competitively antagonised the responses to the
A2A-selective agonist CGS 21680 (Fig. 8e,f) yielding pA2 (-log KB)
values of 7.79 ± 0.15 (n = 3) and 8.64 ± 0.12 (n = 5) for SCH 58261
and ZM 241385 respectively. Increasing concentrations of XAC
and ZM 241385 (Fig. 8g-h) both gave sequential rightwards shifts
of the concentration response curve for BAY 60-6583 at lower
antagonist concentrations but significantly depressed the Emax at
the highest antagonist concentrations used (Table 3; 1 mM,
p < .0001 Fig. 8g, p < 0.001 Fig. 8h).
Increasing concentrations of the A2BAR selective antagonist PSB
603 significantly depressed the maximum response to NECA(p < .01; Table 2; one-way ANOVA) but did not significantly affect
the EC50 (Fig. 9a, Table 2). PBS 603 also appeared to depress the
maximum response to adenosine (p < .01; Table 2), however this
was accompanied with a small significant shift of the EC50 value
to higher against concentrations (Fig. 9b, Table 2). PSB 603 pro-
duced a larger shift in the EC50 for BAY 60 6583 (Fig. 9c) although
the effect on the smaller maximum response of BAY 60 6583 was
not well defined (Table 2). PSB 603 pre-incubation, however, did
not affect the response to forskolin (Fig. 9d) or CGS 21680 (Fig. 9e).
The non-competitive antagonism of the NECA- and adenosine-
mediated stimulation of cAMP production by PSB 603 suggests a
negative allosteric mode of action at A2BARs. This is consistent with
the incomplete attenuation of the response to NECA and adenosine
shown in Fig. 6a and b, indicative of a saturable allosteric effect. To
further investigate this phenomenon, we have also looked in detail
at the kinetics of the response to NECA obtained in the presence of
different concentrations of PSB 603 (Fig. 10). In comparison to the
kinetics of the antagonism obtained with ZM 241385, there are
two characteristics of the kinetics obtained with NECA in the pres-
ence of PSB 603 which are notable: (1) the antagonism by PSB 603
of the peak response to NECA reaches a limiting level leaving a
residual response (circa 20%) (Fig. 10a) that is not observed with
ZM 241385 (Fig. 10b) and (2) the time to the peak NECA response
decreases in the presence of increasing concentrations of PSB 603
(Fig. 10a).
4. Discussion
In the present study we have used a real-time kinetic assay of
changes in cAMP-stimulated PKA activation (GloSensorTM; [25,26])
to investigate the molecular pharmacology of the A2BAR -
selective antagonist PSB 603 [6,16] in HEK 293 cells, endogenously
expressing the human A2BAR [21]. The GloSensorTM biosensor pro-
vided a robust kinetic profile of the responses to forskolin and
NECA that were concentration dependent and characterised by a
peak in luminescence occurring between 5 and 20 min.
BAY 60-6583 acted as a partial agonist of the A2BAR cAMP
response in these cells. This was evident from both the lower
)b()a(
)d()c(
Fig. 6. Antagonism of agonist-stimulated cAMP Glosensor responses by increasing concentrations of adenosine receptor antagonists. Competition curves for (a) NECA (10
mM), (b) adenosine (10 lM), (c) BAY 60-6583 (1 lM) or (d) CGS 21680 (1 lM) stimulated cAMP responses following 30 min pre-incubation with XAC, PSB 603, ZM 241385 or
SCH 58261. Data represent mean ± S.E.M of the peak luminescence response in individual experiments carried out in triplicate. Data are expressed as% of the peak
luminescence response to each agonist obtained in the absence of antagonist for (a) seven (PSB), six (XAC), five (ZM 241385) or four (SCH 58261) separate experiments
performed in triplicate. The residual response following 10 mM PSB 603 pre-incubation is significantly different to that seen with following stimulation with vehicle alone (1
way ANOVA, ***P < .001); (b) of four (XAC), five (PSB 603, ZM 241385) or six (SCH 58261) separate experiments performed in triplicate. The residual luminescence response
following 10 mM PSB 603 pre-incubation is significantly different to that seen with following stimulation with vehicle alone (1 way ANOVA, ***P < .001); (c) five (XAC, ZM
241385, SCH 58261) or seven (PSB 603) separate experiments performed in triplicate; (d) five (XAC), six (PSB 603), seven (SCH 58261) or eight (ZM 241385) separate
experiments performed in triplicate.
Fig. 7. The influence of SCH 58261 on the inhibition of NECA-stimulated cAMP
production by PSB 603. Inhibition of the peak NECA (10 lM) stimulated responses
following 30 min pre-incubation with the A2b selective antagonist PSB 603 (n = 4)
in the presence or absence of the A2a selective antagonist SCH 58261 (100 nM).
Data represent mean ± S.E.M of the peak luminescence response in individual
experiments carried out in triplicate. Data are expressed as a percentage of the peak
luminescence response to10 lMNECA obtained in the absence of antagonist in each
individual experiment.
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high concentrations of BAY 60-6583 to antagonise the response
to a high concentration of NECA (Fig. 5a). Hinz et al., have also
observed partial agonism with BAY 60-6583 in both endogenous
and transfected lines [35], although Thim et al. [6] reported a full
agonist response which would be expected at the higher receptor
expression levels achieved with retroviral transfection approaches.
A notable feature of the response to high concentrations of
NECA and BAY 60-6583 was that the decay in GloSensorTM lumines-
cence was more rapid than that seen with lower agonist concentra-
tions or indeed with all concentrations of forskolin. This is most
likely a consequence of receptor desensitization at the high con-
centrations of NECA or BAY 60-6583 employed and suggests that
the GloSensorTM system is accurately reporting the dynamic state
of cAMP levels within the cells, and hence the extent of receptor
activation. To examine receptor activation more directly we were
able to use adenosine as the agonist and show that the lumines-
cence signal rapidly declines to basal levels when the adenosine
metabolising enzyme adenosine deaminase is added at the peak
of the agonist response. Without the continued stimulus on the
active receptor, residual cAMP is rapidly exported from the cell
and/or hydrolysed by phosphodiesterases. It follows therefore that
)b()a(
(c)
(e) (f)
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Fig. 8. Influence of adenosine receptor antagonists on concentration-response curves to NECA, Adenosine, CGS 21680 and BAY 60-6583. NECA (a-c), Adenosine (d), CGS 21680
(e-f) and BAY 60-6583 (g-h) concentration response curves were obtained in the presence and absence of increasing concentrations of (a,g) XAC, (b,f,h) ZM 241385 or (c-e)
SCH 58261. Values are mean ± S.E.M. of (a,f-h) five, (b,d) four or (c,e) three separate experiments carried out in triplicate. Data represent peak luminescence response and are
expressed as a percentage of the peak luminescence response to 10 lM NECA, 100 lM Adenosine, 10 lM CGS 21680 or 10 lM BAY 60-6583 obtained in the absence of
antagonist in each individual experiment.
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Table 3
BAY 60-6583 pEC50 and Emax values obtained in the presence of increasing concentrations of XAC or ZM 241385.
XAC ZM 241385
Antagonist (nM) pEC50 Emax pEC50 Emax
0 6.42 ± 0.04 103.50 ± 5.27 6.46 ± 0.08 100.80 ± 4.61
100 5.88 ± 0.06** 96.56 ± 4.80 5.85 ± 0.06*** 99.03 ± 7.14
300 5.65 ± 0.04*** 85.63 ± 5.04 5.67 ± 0.06**** 80.84 ± 8.36
1000 5.03 ± 0.18**** 55.89 ± 7.86**** 5.14 ± 0.12**** 54.08 ± 8.41***
pEC50 and Emax values obtained for BAY 60-6583 obtained in the presence of increasing concentrations of XAC or ZM 241385. EMAX values are expressed as a percentage of the
response obtained with 10 lM BAY 60-6583. Significant differences to that seen in the absence of antagonist with each agonist are indicated (**p < .01, ***p < .001,****p < .0001
1-way ANOVA). Data are expressed as mean ± S.E.M. of 5 separate experiments.
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NECA or BAY 60-6583 concentrations could result from a reduced
pool of active receptor which would be apparent due to desensiti-
zation of the receptor. This A2BAR rapid agonist-driven desensitiza-
tion has been noted previously and has been shown to be mediated
by GRK2 that leads to b-arrestin-2 dependent receptor internalisa-
tion and subsequent re-sensitization or degradation [36–39].
Consistent with previous reports [21], a pharmacological analy-
sis of the GloSensorTM responses to NECA and adenosine indicated
that they were largely mediated by A2BARs. The responses were
antagonised by the A2BAR selective antagonist PSB 603. The selec-
tive A2AAR antagonist ZM 241385 only antagonised responses to
NECA and adenosine at higher concentrations (pKi = 8.1 and 7.9
respectively; Table 1) than those required to selectively inhibit
the A2AAR (pKi > 9.0; [24,33]). Furthermore, the more selective
A2AAR antagonist SCH 58261 [34] failed to inhibit the response
to NECA at all concentrations studied in keeping with its known
affinity for the A2BAR (pKi 6.0; [24]). A small inhibition of the
responses to BAY 60-6583 and adenosine by SCH 58261 was only
observed at the highest concentration of this A2AAR-antagonist
used. This is likely to be due to the fact that SCH 58261 will start
to inhibit the A2B receptor at concentrations in the micromolar
range. The A2AAR -selective agonist CGS 21680, however, was able
to stimulate a small response in these cells (18.6% of that achieved
with NECA) and this had an antagonist profile (Fig. 6d) consistent
with an A2AAR -mediated response. This response to CGS 21680
was antagonised competitively by ZM 241385 and SCH 58261 with
pKi values of 9.4 and 8.2 respectively (Fig. 8e) but was not affected
by PSB 603 at concentrations up to 10 lM. Taken together, these
data are consistent with the presence of both A2AARs and A2BARs
in HEK 293G cells regulating the formation of cAMP.
It was notable that both XAC and ZM241385 decreased the EMAX
for BAY 80-6583 at the highest concentrations used. This is likely
to be a result of a combination of: (a) the partial agonist nature
of BAY 60-6583; (b) the transient nature of the Glosensor cAMP
response produced by BAY 60-6583 and (c) the long residence time
on the receptor of the two antagonists at high concentrations lead-
ing to hemi-equilibrium conditions. i.e. At the highest concentra-
tion of XAC and ZM241385 used, it is likely that the antagonist
dissociates too slowly to allow the increasing agonist concentra-
tions to reach equilibrium and overcome the antagonism before
the agonist response wanes.
The presence of a 20% contribution from A2AAR to the cAMP
responses to NECA and adenosine (predicted by the data obtained
with CGS 21680) in this cell line suggests that only an 80% inhibi-
tion of these latter two agonists would be expected with the highly
selective A2BAR antagonist PSB 603. This was what was observed
(Fig. 6). However, inclusion of 100 nM SCH 58261 along with PSB
603 (Fig. 7) gave no indication of an A2AAR component in the
response to NECA. This was also the case when concentration-
response curves to NECA were analysed in the presence of increas-
ing concentrations of SCH 58261 (Fig. 8c). These data suggest that
cAMP responses to NECA and adenosine are only mediated via theA2BAR in this endogenously expressing cell line. The most likely
explanation for the failure to observe a significant A2AAR compo-
nent in the responses to NECA and adenosine is that a rapid
A2AAR heterologous desensitization occurs [40] as a result of the
activation of A2BAR.
The ability of A2BAR activation to over-ride any concomitant
activation of A2AAR is also suggested by the data obtained with
BAY 60-6583 and CGS 21680 in combination (Fig. 5). In Fig. 5a a
classical demonstration of the partial agonist effect of BAY 60-
6583 was demonstrated. However, in Fig. 5b where the interaction
between BAY 60-6583 and CGS 21680 is investigated, the
responses to the two agonists were simply additive at low concen-
trations of each agonist, but reached a maximum that was entirely
determined by the maximum response to BAY 60-6583. These data
support the contention that the overall response to a combination
of A2A and A2B receptor stimulation is largely determined by the
larger A2B signal in this cell line.
An alternative explanation for the limited 80% inhibition of the
cAMP responses to NECA and adenosine observed with PSB 603
(but not with XAC or ZM 241385) is that it is acting allosterically
and the negative cooperative effect reaches a saturable effect
[17–20]. In keeping with this hypothesis, the effect of increasing
concentrations of PSB 603 on the concentration responses curves
to NECA (Fig. 9a) and adenosine (Fig. 9b) were not consistent with
competitive antagonism. In the case of NECA, the maximal
response was significantly decreased by increasing concentrations
of PSB 603 without significant effect on the pEC50 values (Table 2).
The decrease in maximal response obtained with PSB 603 was not
a consequence of off-target effects since concentration-response
curves to both forskolin and CGS 21680 were completely unaf-
fected at concentration of PSB 603 up to 300 nM. Furthermore,
the small shift in pEC50 that accompanied the marked reduction
in EMAX observed in response to adenosine is consistent with the
probe dependence (i.e. which ligand is occupying the orthosteric
site) of an allosteric mechanism of action [17–20].
As previously reported [35], BAY 60-6583 acted as a partial
A2BAR agonist in the present studies. Interestingly, PSB 603 was
able to completely attenuate the Glosensor responses to this lower
efficacy agonist. However, as with the more efficacious agonists
NECA and adenosine, the antagonism produced by PSB 603 of the
BAY 60-6583 responses was not completely compatible with a
simple competitive interaction. These observations would be com-
patible with the probe dependence referred to above [17–20].
Analysis of the kinetic profiles of the responses to NECA in the
presence and absence of PSB 603 or ZM 241385 also suggested a
different mechanism of action for these two antagonists. In com-
parison to the kinetics observed with ZM 241385, the antagonism
by PSB 603 reached a limiting level (evidence of saturation) leaving
a residual response (circa 20%) to NECA that was not observed with
ZM 241385. Furthermore, the peak response to NECA was obtained
at shorter incubation times in the presence of increasing concen-
trations of PSB 203. This was not observed with ZM 241385 where
the peak responses to NECA in the presence of 100 or 300 nM ZM
F)b()a(
(c) (d)
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Fig. 9. Influence of PSB 603 on concentration-response curves to adenosine receptor agonists and forskolin. Influence of increasing concentrations of PSB 603 on the agonist
concentration-response curves for (a) NECA, (b) Adenosine (c) BAY 60-6583, (d) forskolin (FSK) and (e) CGS 21680. Values represent mean ± S.E.M. obtained in (a) four, (b,e)
seven or (c,d) six separate experiments carried out in triplicate. Data represent the peak luminescence response and are expressed as a percentage of the peak luminescence
response obtained with 10 lM NECA, 10 lM adenosine, 1 lM BAY 60-6583, 10 lM FSK or 1 lM CGS 21680 in the absence of antagonist in each individual experiment.
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(a)
(b)
Fig. 10. Kinetic profile of NECA-stimulated cAMP GloSensor luminescence obtained
in the presence of increasing concentrations of (a) PSB 603 or (b) ZM241385. Data
(mean ± S.E.M.) are expressed as a percentage of the peak luminescence response to
10 lM NECA obtained in the absence of antagonist in six (PSB 603) or five (ZM
241385) separate experiments. In each experiment triplicate determinations were
made.
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for a competitive antagonist. Taken together, these data suggest
that the mechanism of action of PSB 603 at the A2BAR is due to a
negatively cooperative effect on the binding affinity and/or efficacy
of agonists acting via the orthosteric site. Previous works with
3H-PSB-603 [6,16] have provided some evidence that PSB 603
may bind to a different set of amino acids to those used by the
endogenous ligand adenosine, and this would be consistent with
an allosteric mechanism of action.
In conclusion, the data presented here suggest that PSB 603 acts
as a highly selective negative allosteric modulator of A2BAR -
mediated increases in cAMP accumulation in HEK 293 cells
endogenously expressing the human A2BAR. Interestingly, other
positive and negative allosteric modulators of this receptor have
recently been reported [41]. Allosteric modulation of the human
A2BAR therefore represents a novel route to the development of
therapeutic agents to treat conditions such as inflammation and
ischemia where adenosine levels can be quite high (and could
reduce the effectiveness of competitive receptor antagonists).Acknowledgements
This work was supported by the Medical Research Council
(grant number G0800006). We thank Promega Corporation for
supplying the HEK293G cells. LTM held a National Health and
Medical Research Council (NHRMC) postdoctoral research fellow-
ship and is now an ARC DECRA Postdoctoral Research Fellow.Author contributions
Participated in research design: Goulding, May, Hill.
Conducted experiments: Goulding.
Performed data analysis: Goulding, May, Hill.Wrote or contributed to the writing of the manuscript: Gould-
ing, May, Hill.Statement of conflicts of interest
The authors declare no conflicts of interest.
References
[1] B.B. Fredholm, I.J. AP, K.A. Jacobson, J. Linden, C.E. Muller, International Union
of Basic and Clinical Pharmacology. LXXXI. Nomenclature and classification of
adenosine receptors–an update, Pharmacol. Rev. 63 (2011) 1–34.
[2] K.A. Jacobson, Introduction to adenosine receptors as therapeutic targets,
Handb. Exp. Pharmacol. (2009) 1–24.
[3] C.E. Muller, K.A. Jacobson, Recent developments in adenosine receptor ligands
and their potential as novel drugs, Biochim. Biophys. Acta 2011 (1808) 1290–
1308.
[4] V.P. Jaakola, M.T. Griffith, M.A. Hanson, V. Cherezov, E.Y. Chien, J.R. Lane, et al.,
The 2.6 angstrom crystal structure of a human A2A adenosine receptor bound
to an antagonist, Science 322 (2008) 1211–1217.
[5] F. Xu, H. Wu, V. Katritch, G.W. Han, K.A. Jacobson, Z.G. Gao, et al., Structure of
an agonist-bound human A2A adenosine receptor, Science 332 (2011) 322–
327.
[6] D. Thimm, A.C. Schiedel, F.F. Sherbiny, S. Hinz, K. Hochheiser, D.C. Bertarelli,
et al., Ligand-specific binding and activation of the human adenosine A(2B)
receptor, Biochemistry 52 (2013) 726–740.
[7] S. Ryzhov, S.V. Novitskiy, R. Zaynagetdinov, A.E. Goldstein, D.P. Carbone, I.
Biaggioni, et al., Host A(2B) adenosine receptors promote carcinoma growth,
Neoplasia 10 (2008) 987–995.
[8] C.X. Sun, H. Zhong, A. Mohsenin, E. Morschl, J.L. Chunn, J.G. Molina, et al., Role
of A2B adenosine receptor signaling in adenosine-dependent pulmonary
inflammation and injury, J. Clin. Invest. 116 (2006) 2173–2182.
[9] H.J. Xiang, Z.C. Liu, D.S. Wang, Y. Chen, Y.L. Yang, K.F. Dou, Adenosine A(2b)
receptor is highly expressed in human hepatocellular carcinoma, Hepatol. Res.
36 (2006) 56–60.
[10] H. Zhong, L. Belardinelli, T. Maa, D. Zeng, Synergy between A2B adenosine
receptors and hypoxia in activating human lung fibroblasts, Am. J. Respir. Cell
Mol. Biol. 32 (2005) 2–8.
[11] Y. Zhou, D.J. Schneider, E. Morschl, L. Song, M. Pedroza, H. Karmouty-Quintana,
et al., Distinct roles for the A2B adenosine receptor in acute and chronic stages
of bleomycin-induced lung injury, J. Immunol. 186 (2011) 1097–1106.
[12] R.V. Kalla, J. Zablocki, Progress in the discovery of selective, high affinity A(2B)
adenosine receptor antagonists as clinical candidates, Purinergic Signal 5
(2009) 21–29.
[13] G. Ortore, A. Martinelli, A2B receptor ligands: past, present and future trends,
Curr. Top. Med. Chem. 10 (2010) 923–940.
[14] A. El Maatougui, J. Azuaje, M. Gonzalez-Gomez, G. Miguez, A. Crespo, C.
Carbajales, et al., Discovery of potent and highly selective A2B adenosine
receptor antagonist chemotypes, J. Med. Chem. 59 (2016) 1967–1983.
[15] S. Basu, D.A. Barawkar, V. Ramdas, Y. Waman, M. Patel, A. Panmand, et al., A2B
adenosine receptor antagonists: design, synthesis and biological evaluation of
novel xanthine derivatives, Eur. J. Med. Chem. 127 (2017) 986–996.
[16] T. Borrmann, S. Hinz, D.C. Bertarelli, W. Li, N.C. Florin, A.B. Scheiff, et al., 1-
Alkyl-8-(piperazine-1-sulfonyl)phenylxanthines: development and
characterization of adenosine A2B receptor antagonists and a new
radioligand with subnanomolar affinity and subtype specificity, J. Med.
Chem. 52 (2009) 3994–4006.
[17] T. Kenakin, Functional selectivity and biased receptor signaling, J. Pharmacol.
Exp. Ther. 336 (2011) 296–302.
[18] T.P. Kenakin, 7TM receptor allostery: putting numbers to shapeshifting
proteins, Trends Pharmacol. Sci. 30 (2009) 460–469.
[19] P. Keov, P.M. Sexton, A. Christopoulos, Allosteric modulation of G protein-
coupled receptors: a pharmacological perspective, Neuropharmacology 60
(2011) 24–35.
[20] L.T. May, K. Leach, P.M. Sexton, A. Christopoulos, Allosteric modulation of G
protein-coupled receptors, Annu. Rev. Pharmacol. Toxicol. 47 (2007) 1–51.
[21] J. Cooper, S.J. Hill, S.P. Alexander, An endogenous A2B adenosine receptor
coupled to cyclic AMP generation in human embryonic kidney (HEK 293) cells,
Br. J. Pharmacol. 122 (1997) 546–550.
[22] K.N. Klotz, J. Hessling, J. Hegler, C. Owman, B. Kull, B.B. Fredholm, et al.,
Comparative pharmacology of human adenosine receptor subtypes -
characterization of stably transfected receptors in CHO cells, Naunyn-
Schmiedebergs Arch. Pharmacol. 357 (1998) 1–9.
[23] J. Linden, T. Thai, H. Figler, X. Jin, A.S. Robeva, Characterization of human A(2B)
adenosine receptors: radioligand binding, western blotting, and coupling to G
(q) in human embryonic kidney 293 cells and HMC-1 mast cells, Mol.
Pharmacol. 56 (1999) 705–713.
[24] E. Ongini, S. Dionisotti, S. Gessi, E. Irenius, B.B. Fredholm, Comparison of CGS
15943, ZM 241385 and SCH 58261 as antagonists at human adenosine
receptors, Naunyn Schmiedebergs Arch. Pharmacol. 359 (1999) 7–10.
[25] B.F. Binkowski, B.L. Butler, P.F. Stecha, C.T. Eggers, P. Otto, K. Zimmerman, et al.,
A luminescent biosensor with increased dynamic range for intracellular cAMP,
ACS Chem. Biol. 6 (2011) 1193–1197.
66 J. Goulding et al. / Biochemical Pharmacology 147 (2018) 55–66[26] F. Fan, B.F. Binkowski, B.L. Butler, P.F. Stecha, M.K. Lewis, K.V. Wood, Novel
genetically encoded biosensors using firefly luciferase, ACS Chem. Biol. 3
(2008) 346–351.
[27] E.M. Rosethorne, R.J. Turner, R.A. Fairhurst, S.J. Charlton, Efficacy is a
contributing factor to the clinical onset of bronchodilation of inhaled beta
(2)-adrenoceptor agonists, Naunyn Schmiedebergs Arch. Pharmacol. 382
(2010) 255–263.
[28] R. Irannejad, J.C. Tomshine, J.R. Tomshine, M. Chevalier, J.P. Mahoney, J.
Steyaert, et al., Conformational biosensors reveal GPCR signalling from
endosomes, Nature 495 (2013) 534–538.
[29] J.O. DiRaddo, E.J. Miller, H.A. Hathaway, E. Grajkowska, B. Wroblewska, B.B.
Wolfe, et al., A real-time method for measuring cAMP production modulated
by Galphai/o-coupled metabotropic glutamate receptors, J. Pharmacol. Exp.
Ther. 349 (2014) 373–382.
[30] J. Gilissen, P. Geubelle, N. Dupuis, C. Laschet, B. Pirotte, J. Hanson, Forskolin-
free cAMP assay for Gi-coupled receptors, Biochem. Pharmacol. 98 (2015)
381–391.
[31] S. Lazareno, N.J. Birdsall, Estimation of antagonist Kb from inhibition curves in
functional experiments: alternatives to the Cheng-Prusoff equation, Trends
Pharmacol. Sci. 14 (1993) 237–239.
[32] I. Feoktistov, I. Biaggioni, Pharmacological characterization of adenosine A2B
receptors: studies in human mast cells co-expressing A2A and A2B adenosine
receptor subtypes, Biochem. Pharmacol. 55 (1998) 627–633.
[33] S.M. Poucher, J.R. Keddie, P. Singh, S.M. Stoggall, P.W. Caulkett, G. Jones, et al.,
The in vitro pharmacology of ZM 241385, a potent, non-xanthine A2a selective
adenosine receptor antagonist, Br. J. Pharmacol. 115 (1995) 1096–1102.[34] C. Zocchi, E. Ongini, A. Conti, A. Monopoli, A. Negretti, P.G. Baraldi, et al., The
non-xanthine heterocyclic compound SCH 58261 is a new potent and selective
A2a adenosine receptor antagonist, J. Pharmacol. Exp. Ther. 276 (1996) 398–
404.
[35] S. Hinz, S.K. Lacher, B.F. Seibt, C.E. Muller, BAY60-6583 acts as a partial agonist
at adenosine A2B receptors, J. Pharmacol. Exp. Ther. 349 (2014) 427–436.
[36] S.J. Mundell, J.L. Benovic, E. Kelly, A dominant negative mutant of the G
protein-coupled receptor kinase 2 selectively attenuates adenosine A2
receptor desensitization, Mol. Pharmacol. 51 (1997) 991–998.
[37] S.J. Mundell, R.P. Loudon, J.L. Benovic, Characterization of G protein-coupled
receptor regulation in antisense mRNA-expressing cells with reduced arrestin
levels, Biochemistry 38 (1999) 8723–8732.
[38] S.J. Mundell, A.L. Matharu, E. Kelly, J.L. Benovic, Arrestin isoforms dictate
differential kinetics of A2B adenosine receptor trafficking, Biochemistry 39
(2000) 12828–12836.
[39] D.M. Peters, E.K. Gies, C.R. Gelb, R.A. Peterfreund, Agonist-induced
desensitization of A2B adenosine receptors, Biochem. Pharmacol. 55 (1998)
873–882.
[40] T.M. Palmer, G.L. Stiles, Identification of an A2a adenosine receptor domain
specifically responsible for mediating short-term desensitization,
Biochemistry 36 (1997) 832–838.
[41] M.L. Trincavelli, C. Giacomelli, S. Daniele, S. Taliani, B. Cosimelli, S. Laneri, et al.,
Allosteric modulators of human A2B adenosine receptor, Biochim. Biophys.
Acta 2014 (1840) 1194–1203.
